Last checked at 
(Adds quotes from patient)
LONDON, Sept 3 (Reuters) - A British man who contractedEbola in West Africa has been discharged after successfultreatment with the experimental ZMapp drug, the Royal FreeHospital in London said on Wednesday.
William Pooley, 29, was treated in a special isolation unitafter contracting the deadly disease in August when working as avolunteer nurse in Sierra Leone.
"Following 10 days of successful treatment in the high levelisolation unit - the only one in the UK - Mr Pooley is beingdischarged from the Royal Free Hospital today," the hospitalsaid in a statement on its website.
"He was flown to the hospital on Sunday 24 August 2014 andwas treated with the experimental drug ZMapp," it added.
Pooley later told reporters at a news conference he thoughthe had been fortunate.
"I was very lucky in several ways," he said. "Firstly in thestandard of care that I received, which is a world apart fromwhat people are receiving in West Africa at the moment despitelot of organisations' best efforts.
"The other difference to a lot of Ebola cases (is) that mysymptoms never progressed to the worst stages of the disease. Ihad some unpleasant symptoms but nothing compared to some of theworst of the disease."
Governments and aid organizations have scrambled to containthe disease, which according to the World Health Organization(WHO) has killed more than 1,500 in West Africa since March.
ZMapp is one of several treatments for Ebola underdevelopment. The drug, although never tested in humans, gainedattention this summer when two American aid workers whocontracted Ebola in Liberia were cured after receiving it.
ZMapp, which uses antibodies from tobacco plants, is made bythe privately held Mapp Biopharmaceutical Inc, based in SanDiego, California.
The U.S. Department of Health and Human Services has said afederal contract worth up to $42.3 million would help acceleratetesting of the treatment.
It said Mapp would manufacture a small amount of ZMapp forearly stage safety studies and animal studies needed to proveits effectiveness and safety in people.
Human safety trials are due to begin this week on a vaccinefrom GlaxoSmithKline Plc and later this year on one fromNewLink Genetics Corp. (Reporting by Stephen Addison; editing by Sarah Young)
